Duration of CYP3A inhibition by clarithromycin.

被引：0
|
作者：
Gorski, JC [1 ]
Wang, Z [1 ]
Hall, SD [1 ]
机构：
[1] Indiana Univ, Div Clin Pharmacol, Indianapolis, IN USA
来源：
CLINICAL PHARMACOLOGY & THERAPEUTICS | 2002年 / 71卷 / 02期
关键词：
D O I：
暂无
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
引用
收藏
页码：P33 / P33
页数：1
相关论文
共 50 条
  • [1] Irreversible inhibition of intestinal cytochrome 3A (CYP3A) by clarithromycin.
    Pinto, AG
    Chalasani, N
    Hall, SD
    Ali, A
    Hamman, M
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2003, 73 (02) : P61 - P61
  • [2] Age and sex effect on duration of CYP3A inhibition by clarithromycin
    Wang, YH
    Gorski, JC
    Hamman, MA
    Hall, SD
    [J]. DRUG METABOLISM REVIEWS, 2004, 36 : 287 - 287
  • [3] Differential inhibition of intestinal and hepatic CYP3A by clarithromycin in vivo.
    Gorski, JC
    Hall, SD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2002, 71 (02) : P28 - P28
  • [4] Itraconazole and Clarithromycin as Ketoconazole Alternatives for Clinical CYP3A Inhibition Studies
    Ke, A. B.
    Zamek-Gliszczynski, M. J.
    Higgins, J. W.
    Hall, S. D.
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 2014, 95 (05) : 473 - 476
  • [5] Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin
    Sara K. Quinney
    Srikar R. Malireddy
    Raj Vuppalanchi
    Mitchell A. Hamman
    Naga Chalasani
    J. Christopher Gorski
    Stephen D. Hall
    [J]. European Journal of Clinical Pharmacology, 2013, 69 : 439 - 448
  • [6] Rate of onset of inhibition of gut-wall and hepatic CYP3A by clarithromycin
    Quinney, Sara K.
    Malireddy, Srikar R.
    Vuppalanchi, Raj
    Hamman, Mitchell A.
    Chalasani, Naga
    Gorski, J. Christopher
    Hall, Stephen D.
    [J]. EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY, 2013, 69 (03) : 439 - 448
  • [7] Physiologically Based Pharmacokinetic Model of Mechanism-Based Inhibition of CYP3A by Clarithromycin
    Quinney, Sara K.
    Zhang, Xin
    Lucksiri, Aroonrut
    Gorski, J. Christopher
    Li, Lang
    Hall, Stephen D.
    [J]. DRUG METABOLISM AND DISPOSITION, 2010, 38 (02) : 241 - 248
  • [8] The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin
    Gorski, JC
    Jones, DR
    Haehner-Daniels, BD
    Hamman, MA
    O'Mara, EM
    Hall, SD
    [J]. CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (02) : 133 - 143
  • [9] Effects of CYP3A inhibition on the metabolism of cilostazol
    Suri, A
    Forbes, WP
    Bramer, SL
    [J]. CLINICAL PHARMACOKINETICS, 1999, 37 (Suppl 2) : 61 - 68
  • [10] Effects of CYP3A Inhibition on the Metabolism of Cilostazol
    Ajit Suri
    William P. Forbes
    Steven L. Bramer
    [J]. Clinical Pharmacokinetics, 1999, 37 : 61 - 68
12345